Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update Guidelines

  


Authors: Tew, W. P.; Lacchetti, C.; Kohn, E. C.; for the PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel
Title: Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update
Abstract: ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
Keywords: ovarian neoplasms; ovary tumor; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; humans; human; female; poly(adp-ribose) polymerase inhibitors
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 33
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-11-20
Start Page: 3878
End Page: 3881
Language: English
DOI: 10.1200/jco.22.01934
PUBMED: 36150092
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142401458&doi=10.1200%2fJCO.22.01934&partnerID=40&md5=5ed0dd19f5a73c361b663cc499df51e5
Notes: Article -- Export Date: 1 December 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. William P Tew
    244 Tew
Related MSK Work